CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The HIV antiretroviral drug Viramune can cause sometimes deadly liver damage but remains a key option for many patients, U.S. health officials warned on Wednesday. The Food and Drug Administration said doctors should weigh benefits and risks before prescribing the nonnucleoside reverse transcriptase inhibitor, manufactured by Boehringer Ingelheim. No serious liver toxicity or deaths have been reported when a single dose was given to prevent mother-to-child transmission of the deadly HIV virus that causes AIDS, the FDA said. Viramune, also known by its generic name nevirapine, is distributed for that use in African countries as part of President George Bush's effort to fight the spread of AIDS. The name-brand drug is also used in the United States. Controversy has swirled recently in Africa, with South Africa's ruling African National Congress accusing U.S. officials of conspiring with Boehringer Ingelheim, a private company based in Germany, to hide nevirapine's side effects. U.S. health officials dispute the charge. The FDA, in a statement, said cases of liver damage that produce a rash, fever, or other symptoms were more common with nevirapine than with other HIV-fighting drugs. Some instances have been fatal, including some in pregnant women. Females and patients with higher counts of infection-fighting CD4 immune system cells have greater risks of developing liver damage, the FDA said. The FDA said side-effect warnings had recently been revised on the drug's prescribing information. "In spite of the potential for serious and life-threatening liver toxicity and skin rashes with nevirapine, there are multiple reasons why nevirapine remains an important part of an HIV treatment regimen for many HIV-infected individuals worldwide," the FDA said in a statement. A spokeswoman for Boehringer Ingelheim said there would be no change in the company's policy of offering Viramune free of charge to developing countries for preventing mother-to-child transmissions of HIV. "There is no consequence for our donation or for supply of the drug for continuous treatment at reduced prices in developing countries," the spokeswoman said. "We do not expect any major effects on the behavior of doctors or on our sales as a result of the FDA warning." (Reuters)
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Here Are Our 2024 Election Predictions. Will They Come True?
November 07 2023 1:46 PM
Meet all 37 of the queer women in this season's WNBA
April 17 2024 11:24 AM
17 Celebs Who Are Out & Proud of Their Trans & Nonbinary Kids
November 30 2023 10:41 AM
Which State Is the Queerest? These Are the States With the Most LGBTQ+ People
December 11 2023 10:00 AM
These 27 Senate Hearing Room Gay Sex Jokes Are Truly Exquisite
December 17 2023 3:33 PM
10 Cheeky and Homoerotic Photos From Bob Mizer's Nude Films
November 18 2023 10:05 PM
42 Flaming Hot Photos From 2024's Australian Firefighters Calendar
November 10 2023 6:08 PM
These Are the 5 States With the Smallest Percentage of LGBTQ+ People
December 13 2023 9:15 AM
Here are the 15 gayest travel destinations in the world: report
March 26 2024 9:23 AM
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Latest Stories
04/30/24
April 30 2024 10:45 PM
Sniffies now has filters for age, body type & endowment
April 30 2024 10:20 PM
Biden admin moves to protect LGBTQ+ kids in foster care
April 30 2024 5:55 PM
Pride
Yahoo FeedGifts for your mother and your MOTHER: Celebrating every mom on Mother’s Day
April 30 2024 5:43 PM